Navigation Links
Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract and Increase Funding for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
Date:10/1/2013

SAN DIEGO, Oct. 1, 2013 /PRNewswire/ -- Pfenex Inc. today announced that the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA), has modified its prime contract and simultaneously exercised an option associated with the existing Pfenex contractual relationship begun in July, 2010. This extends the prime contract and increases the funding to support the development of a next generation rPA-based anthrax vaccine based on rPA produced in its platform technology, Pfēnex Expression Technology™.  The increase in funding of approximately $8.0 million brings the total funding available to approximately $23.9 million over the course of the contract if all options are exercised. During the contract's base period, Pfenex demonstrated that a strongly immunogenic, stable and protective form of rPA could be expressed and recovered from the highly efficient fermentation of a strain of P. fluorescens engineered to produce rPAThe exercise of this option allows for the completion of preclinical studies, implementation of analytical methods and cGMP manufacturing.

"We are pleased with the results and progress provided by Pfenex's recombinant platform technology to the production of a next generation anthrax vaccine," stated Bertrand C. Liang, Chief Executive Officer. "The exercise of this option and increase in funding by BARDA enables Pfenex and BARDA to continue our successful partnership sharing a common objective to develop an anthrax vaccine with a process capable of achieving the goals of the Strategic National Stockpile for the U. S. Government, including production, shelf life, and administration improvements."

About Pfenex Inc.  
Pfenex Inc. is a biotechnology company developing biosimilars and innovative vaccines to address unmet and growing global healthcare need
'/>"/>

SOURCE Pfenex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. Nuisance seaweed found to produce compounds with biomedical potential
2. MADRID-MIT M+Vision Consortium hosts Biomedical Innovation Conference 2012
3. UMass Medical School scientist named 2012 Pew Latin-American Fellow in the Biomedical Sciences
4. 22 of Americas most promising scientists selected as Pew Biomedical Scholars
5. Top young Latin-American scientists named Pew Biomedical Fellows
6. Saladax Biomedical Enters into Master Collaboration Agreement with Bristol-Myers Squibb
7. BGI Tech and BAB jointly develop transgenic mice platform for biomedical research
8. Reproducibility Initiative to increase the value of biomedical research
9. £30 million boost for biomedical engineering research
10. MU celebrates $5 million partnership for advancing biomedical discoveries
11. CNIO participates in the ENCODE project: A stride forward in biomedical research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Card Alliance and the EMV Migration Forum.  ... Card Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. ... leaders promoting adoption of smart card technology. ...
(Date:8/12/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is proud to announce that iMedNet ... technology platform, has led the way to significant and ... 2015.   Q2 2015 and Q1 2015 were, respectively, ... value sold in the company,s 15 year history.  In ...
(Date:8/10/2015)... Germany , August 10, 2015 ... leader in Eye Tracking Technology for more than two ... Tracking Platform for integration into all consumer display formats. ... for seamless integration of eye tracking into consumer tablets, ... augmented reality smart glasses. Omnivision,s leading sensor technology contributes ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... team of scientists, led by Monash University researchers, has ... hospital patients worldwide - a discovery that has the ... of dollars each year. The research published today ... ways to genetically modify the bacterium Clostridium difficile ...
... with the 200th anniversary of the birth of Charles ... Behavioural Processes "Comparative Cognition in Context" was ... Hollis, the special issue features 16 papers original ... by leading researchers in the field of comparative cognition, ...
... issue of BioScience includes the following peer-reviewed articles: ... Science. , Patrick J. Tranel and David P. Horvath. ... including the development of herbicide-resistant crops and a better ... next generation of tools, including genomics, could yield novel ...
Cached Biology News:Monash scientists debug superbug 2BioScience tip sheet, March 2009 2
(Date:8/26/2015)... 26, 2015  The Diabetes Research Institute (DRI), ... Miami Miller School of Medicine, announced today that ... test for the first time a novel transplant ... FDA approved Phase I/II study builds upon decades ... an important first step toward the development of ...
(Date:8/26/2015)... After litigating and negotiating patent infringement claims brought ... United States patent RE43,651 (the ,651 patent), ... United States without any admission or concession of ... a result of the parties, settlement, the US District Court ... dismissed the case without prejudice. Under the terms ...
(Date:8/25/2015)... ... August 25, 2015 , ... ... lesions are cancerous is described by University of Illinois researchers in the ... and photonics. , In “ Breast cancer diagnosis using spatial light interference microscopy ...
(Date:8/25/2015)... PETERSBURG, Fla. , Aug. 25, 2015 /PRNewswire/ ... announced today that it has been awarded Certification ... Quality Assurance (NCQA). NCQA is ... quality. NCQA accredits and certifies a wide range of ... in key areas of performance. "Our ...
Breaking Biology Technology:Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4P2i Settles United States Litigation 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4InformedDNA Achieves NCQA Utilization Management Certification 2
... Polytechnic Institute have developed a new method to harvest ... the creation of self-powered microsensors for more accurate and ... Koratkar, the researchers investigated how the flow of water ... small amounts of electricity. The research team demonstrated the ...
... , , • NT-KO-003, developed by ... neuroprotective effects that does not cause,immunosuppression. ... administered orally, whereas the few treatments available in,Spain require ... • NeuroAdvan, the Phase IIa clinical ...
... 2011 , Convergence Pharmaceuticals Limited ("Convergence"), ... value analgesic,medicines, today announces that the Phase II proof ... lumbosacral,radiculopathy (LSR) has started. LSR is a ... roots in the lumbar region of the spine. Common,features ...
Cached Biology Technology:New graphene discovery boosts oil exploration efforts, could enable self-powered microsensors 2New graphene discovery boosts oil exploration efforts, could enable self-powered microsensors 3Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 2Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 3Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 4Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 5Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802 2Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802 3Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802 4
... Zero -mr agarose is ... no detectable endoosmosis, and is ... high molecular weight proteins or ... varying degrees of molecular sieving ...
... Plus overlay agarose is used for ... IPG strips in place in PROTEAN ... is incorporated to allow monitoring of ... of 0.75% agarose in 1x Tris, ...
The Trans-Blot Plus gel and cassette assembly tray is used to hold the Trans-Blot Plus gel holder cassette, buffer, and other materials for the gel and membrane sandwich during their assembly....
... By incorporating a wide range of ... NX sets a new standard for flexible ... liquid handling including pipetting, dilution, dispensing, ... system thats as powerful and flexible as ...
Biology Products: